



PRODUCT: **OXLUMO®**

COMPANY: Alnylam Pharmaceuticals

THERAPEUTIC AREA & INDICATION:

Treatment of primary hyperoxaluria type 1 (PH1)
to lower urinary oxalate levels in pediatric
and adult patients.

ABOUT THE PRODUCT

From the beginning, Alnylam recognized an urgent need among the primary hyperoxaluria type 1 (PH1) community and committed to advancing a new therapeutic option to support those with this devastating, ultra-rare, genetic disease that affects the kidneys and other organs. OXLUMO® (lumasiran) brings this commitment to life and is a testament to the impact RNAi therapeutics can have in transforming the treatment landscape of life-threatening diseases like PH1. Using improvements in potency, duration, and therapeutic index, OXLUMO leverages Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAC-conjugate technology and is the first RNAi therapeutic approved for use in infants, children, and adults.